Myeloproliferative neoplasms
Drug research and approvals for myeloproliferative neoplasms: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 295 studies of myeloproliferative neoplasms are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.
- Recruiting worldwide: 295
- Trials authorized in Canada: 11
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 295 recruiting on ClinicalTrials.gov ↗- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or…NCT06303193 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Nov 19, 2026
- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsNCT07789574 · Phase 2 · Thomas Ernst, Prof. Dr. med. · starts Nov 1, 2026
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
- A Study of Ropeg-Interferon in People With Polycythemia VeraNCT07886801 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Oct 30, 2026
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).NCT07722611 · Phase 2 / Phase 3 · Merck Sharp & Dohme LLC · starts Oct 29, 2026
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients…NCT06904066 · Phase 1 · National Cancer Institute (NCI) · starts Oct 28, 2026
- Prophylactic DLI-X for Leukemia Relapse After HCTNCT07254793 · Phase 1 · University of Arizona · starts Oct 26, 2026
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNCT07447817 · Phase 2 · John Mascarenhas · starts Oct 23, 2026
- An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the…NCT07883382 · Phase 1 / Phase 2 · Ruijin Hospital · starts Oct 15, 2026
- Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPNNCT07710534 · Phase 2 · Virginia Commonwealth University · starts Sep 16, 2026
Trials Authorized in Canada
The 10 newest of 11; search them all in Canada trials| May 22, 2026 | A phase 1, open-label, multicenter study of inca036978 in participants with myeloproliferative neoplasmsINCA036978 / JAKAVI | Incyte Corporation | Ongoing |
| Nov 18, 2025 | A phase 1, open-label, multicenter study of incb160058 in participants with myeloproliferative neoplasmsINCB160058 / RUXOLITINIB | Incyte Corporation | Ongoing |
| May 10, 2024 | An open-label, multicenter, extension study for patients previously enrolled in studies with pelabresibPELABRESIB (CPI-0610) | CONSTELLATION PHARMACEUTICALS INC. | Pending |
| Nov 16, 2023 | A phase 1, open-label, multicenter study of inca033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative…INCA033989 / RUXOLITINIB | Incyte Corporation | Ongoing |
| Sep 7, 2023 | Protocol 10538, venetoclax in combination with astx727, an all-oral therapy for chronic myelomonocytic leukemia and other mds/mpn with excess blasts…ASTX727 (CEDAZURIDINE-DECITABINE)/ VENETOCLAX | UNIVERSITY HEALTH NETWORK | Ongoing |
| May 31, 2023 | A phase 1, open-label, multicenter, dose escalation study of prt1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / VENETOCLAX / AZACITIDINE | PRELUDE THERAPEUTICS | Closed |
| Dec 21, 2021 | Venetoclax and azacitidine combination therapy for patients with accelerated or blast phase bcr-abl negative myeloproliferative neoplasm (vaamp)VENETOCLAX / AZACITIDINE | PRINCESS MARGARET CANCER CENTRE | Pending |
| Jun 29, 2021 | A phase II open-label study of combined ruxolitinib and enasidenib in patients with accelerated/blast-phase myeloproliferative neoplasm or chronicphase…ENASIDENIB | PRINCESS MARGARET CANCER CENTRE | Ongoing |
| Feb 17, 2021 | A phase 3, double-blind, randomized study to compare the efficacy and safety of luspatercept (ace-536) versus placebo in subjects with myeloproliferative…REBLOZYL (LUSPATERCEPT FOR INJECTION) | Bristol-Myers Squibb | Ongoing |
| Dec 30, 2019 | A phase 2 pilot randomized controlled trial assessing feasibility of thromboprophylaxis with apixaban in jak2-positive myeloproliferative neoplasm patientsAPIXABAN | OTTAWA HOSPITAL RESEARCH INSTITUTE | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA